Reviewing Voyager Therapeutics Inc. (VYGR)’s and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s results

As Biotechnology businesses, Voyager Therapeutics Inc. (NASDAQ:VYGR) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), are affected by compare. This especially applies to their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics Inc. 22 11.62 N/A -2.94 0.00
Vanda Pharmaceuticals Inc. 16 3.61 N/A 0.39 31.68

Table 1 showcases the gross revenue, earnings per share and valuation of Voyager Therapeutics Inc. and Vanda Pharmaceuticals Inc.

Profitability

Table 2 shows Voyager Therapeutics Inc. and Vanda Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics Inc. 0.00% -129.7% -38.2%
Vanda Pharmaceuticals Inc. 0.00% 8.1% 6.6%

Risk & Volatility

Voyager Therapeutics Inc. is 152.00% more volatile than Standard and Poor’s 500 due to its 2.52 beta. Vanda Pharmaceuticals Inc. on the other hand, has 0.35 beta which makes it 65.00% less volatile compared to Standard and Poor’s 500.

Liquidity

Voyager Therapeutics Inc.’s Current Ratio is 6.2 while its Quick Ratio is 6.2. On the competitive side is, Vanda Pharmaceuticals Inc. which has a 5.2 Current Ratio and a 5.2 Quick Ratio. Voyager Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Vanda Pharmaceuticals Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Voyager Therapeutics Inc. and Vanda Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Voyager Therapeutics Inc. 0 0 0 0.00
Vanda Pharmaceuticals Inc. 0 1 1 2.50

The upside potential is 20.48% for Voyager Therapeutics Inc. with consensus price target of $21. Vanda Pharmaceuticals Inc. on the other hand boasts of a $18 consensus price target and a 26.32% potential upside. The data provided earlier shows that Vanda Pharmaceuticals Inc. appears more favorable than Voyager Therapeutics Inc., based on analyst view.

Insider and Institutional Ownership

The shares of both Voyager Therapeutics Inc. and Vanda Pharmaceuticals Inc. are owned by institutional investors at 75.6% and 0% respectively. About 11.5% of Voyager Therapeutics Inc.’s share are held by insiders. On the other hand, insiders held about 3.6% of Vanda Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Voyager Therapeutics Inc. -7.37% -21.17% 5.56% 109.22% 20.47% 134.15%
Vanda Pharmaceuticals Inc. -5.61% -10.43% -22.19% -55.85% -37.59% -52.35%

For the past year Voyager Therapeutics Inc. had bullish trend while Vanda Pharmaceuticals Inc. had bearish trend.

Summary

Vanda Pharmaceuticals Inc. beats on 6 of the 10 factors Voyager Therapeutics Inc.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. The companyÂ’s lead clinical candidate is the VY-AADC01, which is in Phase Ib clinical trial for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for HuntingtonÂ’s disease; VY-FXN01 for Friedreich's ataxia; VY-TAU01, AlzheimerÂ’s disease; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreements with Genzyme Corporation and the University of Massachusetts. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.